cancer - International Biopharmaceutical Industry

Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...

12 October 2022 Volume 5 Issue 3 agents | Antibody

Continue Reading →

news

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executi...

6 June 2022 news cancer | Drug

Continue Reading →

news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...

30 May 2022 news blood | Bristol

Continue Reading →

news

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive gene called KRAS. Upd...

30 May 2022 news Amgen | cancer

Continue Reading →

news

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung ca...

13 May 2022 news cancer | Drug

Continue Reading →

news

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to Cullinan Oncol...

13 May 2022 news cancer | Cullinan

Continue Reading →

news

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug tha...

9 May 2022 news AstraZeneca | breast

Continue Reading →

news

Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Dive Brief: Novartis has suspended production of two cancer drugs at plants in Italy and New Jersey due to “potential quality issues” it identified in its manufact...

9 May 2022 news cancer | Drugs

Continue Reading →

news

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

Cancer Research UK, the world's largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach...

28 April 2022 news cancer | Horizons

Continue Reading →

news

A promising cancer drug leads Regeneron to reconsider its aversion to M&A

Dive Brief: Regeneron has agreed to purchase a young biotechnology company for access to a drug that the buyer believes will be a valuable component in cancer-figh...

25 April 2022 news biotechnology | cancer

Continue Reading →

Current Edition

Upcoming Events

Advertisement

ADCs – From Lab to Clinical Development

Regeneron buys control of cancer drug Libtayo from Sanofi

Merck study results signal blood cancer potential for new type of immunotherapy

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

A promising cancer drug leads Regeneron to reconsider its aversion to M&A

International Biopharmaceutical Industry